S1PR4 signaling attenuates ILT 7 internalization to limit IFN-α production by human plasmacytoid dendritic cells

Journal of Immunology

Volumn 196, Issue 4, 2016, Pages 1579-1590

  Dillmann, Christina ^a   Ringel, Christian ^a   Ringleb, Julia ^a   Mora, Javier ^a   Olesch, Catherine ^a   Fink, Annika F ^a   Roberts, Edward ^b   Brune, Bernhard ^a   Weigert, Andreas ^a  

^a GOETHE UNIVERSITY   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CPG-OLIGONUCLEOTIDE; CYTOKINE; IL10 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 10; LILRA4 PROTEIN, HUMAN; LYSOPHOSPHOLIPID; OLIGODEOXYRIBONUCLEOTIDE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1-PHOSPHATE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CELL CULTURE; CELL DIFFERENTIATION; CELL MOTION; DENDRITIC CELL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; LYSOPHOSPHOLIPIDS; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

EID: 84958554674     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1403168     Document Type: Article

References (63)

1. Swiecki, M., and M. Colonna. 2010. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol. Rev. 234: 142-162.
2. George, P. M., R. Badiger, W. Alazawi, G. R. Foster, and J. A. Mitchell. 2012. Pharmacology and therapeutic potential of interferons. Pharmacol. Ther. 135: 44-53.
3. Ito, T., H. Kanzler, O. Duramad, W. Cao, and Y. J. Liu. 2006. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 107: 2423-2431.
4. Caminschi, I., S. Meuter, and W. R. Heath. 2013. DEC-205 is a cell surface receptor for CpG oligonucleotides. OncoImmunology 2: e23128.
5. Ju, X. S., C. Hacker, B. Scherer, V. Redecke, T. Berger, G. Schuler, H. Wagner, G. B. Lipford, and M. Zenke. 2004. Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene 331: 159-164.
6. Cao, W., D. B. Rosen, T. Ito, L. Bover, M. Bao, G. Watanabe, Z. Yao, L. Zhang, L. L. Lanier, and Y. J. Liu. 2006. Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. J. Exp. Med. 203: 1399-1405.
7. Tavano, B., and A. Boasso. 2014. Effect of immunoglobin-like transcript 7 crosslinking on plasmacytoid dendritic cells differentiation into antigen-presenting cells. PLoS One 9: e89414.
8. Cao, W., L. Bover, M. Cho, X. Wen, S. Hanabuchi, M. Bao, D. B. Rosen, Y. H. Wang, J. L. Shaw, Q. Du, et al. 2009. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J. Exp. Med. 206: 1603-1614.
9. Angelot-Delettre, F., S. Biichle, C. Ferrand, E. Seilles, B. Gaugler, V. Harrivel, M. A. Rosenthal-Allieri, E. Deconinck, P. Saas, and F. Garnache-Ottou. 2012. Intracytoplasmic detection of TCL1-but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis. Cytometry A 81: 718-724.
10. Hartmann, E., B. Wollenberg, S. Rothenfusser, M. Wagner, D. Wellisch, B. Mack, T. Giese, O. Gires, S. Endres, and G. Hartmann. 2003. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 63: 6478-6487.
11. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
12. Tel, J., E. L. Smits, S. Anguille, R. N. Joshi, C. G. Figdor, and I. J. de Vries. 2012. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood 120: 3936-3944.
13. Rivera, J., R. L. Proia, and A. Olivera. 2008. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol. 8: 753-763.
14. Gräler, M. H., G. Bernhardt, and M. Lipp. 1998. EDG6, a novel G-proteincoupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. Genomics 53: 164-169.
15. Spiegel, S., and S. Milstien. 2003. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 4: 397-407.
16. Wang, W., M. H. Graeler, and E. J. Goetzl. 2005. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J. 19: 1731-1733.
17. Schulze, T., S. Golfier, C. Tabeling, K. Räbel, M. H. Gräler, M. Witzenrath, and M. Lipp. 2011. Sphingosine-1-phospate receptor 4 (S1P) deficiency profoundly affects dendritic cell function and TH17-cell differentiation in a murine model. FASEB J. 25: 4024-4036.
18. Ley, S., A. Weigert, B. Weichand, N. Henke, B. Mille-Baker, R. A. Janssen, and B. Brune. 2013. The role of TRKA signaling in IL-10 production by apoptotic tumor cell-activated macrophages. Oncogene 32: 631-640.
19. Sekar, D., C. Hahn, B. Brune, E. Roberts, and A.Weigert. 2012. Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity. Eur. J. Immunol. 42: 1585-1598.
20. Sha, W., C. Olesch, H. Hanaka, O. Radmark, A. Weigert, and B. Brune. 2013. Necrosis in DU145 prostate cancer spheroids induces COX-2/mPGES-1-derived PGE2 to promote tumor growth and to inhibit T cell activation. Int. J. Cancer 133: 1578-1588.
21. Davis, M. D., J. J. Clemens, T. L. Macdonald, and K. R. Lynch. 2005. Sphingosine 1-phosphate analogs as receptor antagonists. J. Biol. Chem. 280: 9833-9841.
22. Guerrero, M., M. Urbano, S. Velaparthi, J. Zhao, M. T. Schaeffer, S. Brown, H. Rosen, and E. Roberts. 2011. Discovery, design and synthesis of the first reported potent and selective sphingosine-1-phosphate 4 (S1P4) receptor antagonists. Bioorg. Med. Chem. Lett. 21: 3632-3636.
23. Guerrero, M., M. Urbano, J. Zhao, M. Crisp, P. Chase, P. Hodder, M. T. Schaeffer, S. Brown, H. Rosen, and E. Roberts. 2012. Discovery, design and synthesis of novel potent and selective sphingosine-1-phosphate 4 receptor (S1P-R) agonists. Bioorg. Med. Chem. Lett. 22: 537-542.
24. Platanias, L. C. 2005. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5: 375-386.
25. Sage, A. P., D. Murphy, P. Maffia, L. M. Masters, S. R. Sabir, L. L. Baker, H. Cambrook, A. J. Finigan, H. Ait-Oufella, G. Grassia, et al. 2014. MHC Class II-restricted antigen presentation by plasmacytoid dendritic cells drives proatherogenic T cell immunity. Circulation 130: 1363-1373.
26. Le Mercier, I., D. Poujol, A. Sanlaville, V. Sisirak, M. Gobert, I. Durand, B. Dubois, I. Treilleux, J. Marvel, J. Vlach, et al. 2013. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res. 73: 4629-4640.
27. Pallotta, M. T., C. Orabona, C. Volpi, C. Vacca, M. L. Belladonna, R. Bianchi, G. Servillo, C. Brunacci, M. Calvitti, S. Bicciato, et al. 2011. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12: 870-878.
28. Fabricius, D., B. Nußbaum, D. Busch, V. Panitz, B. Mandel, A. Vollmer, M. A. Westhoff, C. Kaltenmeier, O. Lunov, K. Tron, et al. 2013. Antiviral vaccines license T cell responses by suppressing granzyme B levels in human plasmacytoid dendritic cells. J. Immunol. 191: 1144-1153.
29. Jahrsdörfer, B., A. Vollmer, S. E. Blackwell, J. Maier, K. Sontheimer, T. Beyer, B. Mandel, O. Lunov, K. Tron, G. U. Nienhaus, et al. 2010. Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 115: 1156-1165.
30. Jähn, P. S., K. S. Zänker, J. Schmitz, and A. Dzionek. 2010. BDCA-2 signaling inhibits TLR-9-agonist-induced plasmacytoid dendritic cell activation and antigen presentation. Cell. Immunol. 265: 15-22.
31. Hervas-Stubbs, S., U. Manchenõ, J. I. Riezu-Boj, A. Larraga, M. C. Ochoa, D. Alignani, C. Alfaro, A. Morales-Kastresana, I. Gonzalez, E. Larrea, et al. 2012. CD8 T cell priming in the presence of IFN-A renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy. J. Immunol. 189: 3299-3310.
32. Kuwana, M. 2002. Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets. Hum. Immunol. 63: 1156-1163.
33. Brinkmann, V., T. Geiger, S. Alkan, and C. H. Heusser. 1993. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J. Exp. Med. 178: 1655-1663.
34. Xia, C. Q., R. Peng, A. V. Chernatynskaya, L. Yuan, C. Carter, J. Valentine, E. Sobel, M. A. Atkinson, and M. J. Clare-Salzler. 2014. Increased IFN-A-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-A production. J. Immunol. 193: 1024-1034.
35. Curtsinger, J. M., J. O. Valenzuela, P. Agarwal, D. Lins, and M. F. Mescher. 2005. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 174: 4465-4469.
36. Julian, M. W., G. Shao, S. Bao, D. L. Knoell, T. L. Papenfuss, Z. C. VanGundy, and E. D. Crouser. 2012. Mitochondrial transcription factor A serves as a danger signal by augmenting plasmacytoid dendritic cell responses to DNA. J. Immunol. 189: 433-443.
37. Lee, B. L., J. E. Moon, J. H. Shu, L. Yuan, Z. R. Newman, R. Schekman, and G. M. Barton. 2013. UNC93B1 mediates differential trafficking of endosomal TLRs. eLife 2: e00291.
38. Tavano, B., R. P. Galao, D. R. Graham, S. J. Neil, V. N. Aquino, D. Fuchs, and A. Boasso. 2013. Ig-like transcript 7, but not bone marrow stromal cell antigen 2 (also known as HM1.24, tetherin, or CD317), modulates plasmacytoid dendritic cell function in primary human blood leukocytes. J. Immunol. 190: 2622-2630.
39. Bao, M., and Y. J. Liu. 2013. Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein Cell 4: 40-52.
40. Röck, J., E. Schneider, J. R. Grun, A. Grutzkau, R. Kuppers, J. Schmitz, and G. Winkels. 2007. CD303 (BDCA-2) signals in plasmacytoid dendritic cells via a BCR-like signalosome involving Syk, Slp65 and PLCgamma2. Eur. J. Immunol. 37: 3564-3575.
41. Kerkmann, M., S. Rothenfusser, V. Hornung, A. Towarowski, M. Wagner, A. Sarris, T. Giese, S. Endres, and G. Hartmann. 2003. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol. 170: 4465-4474.
42. Liao, A. P., M. Salajegheh, C. Morehouse, R. Nazareno, R. G. Jubin, B. Jallal, Y. Yao, and S. A. Greenberg. 2010. Human plasmacytoid dendritic cell accumulation amplifies their type 1 interferon production. Clin. Immunol. 136: 130-138.
43. Mahnke, K., M. Guo, S. Lee, H. Sepulveda, S. L. Swain, M. Nussenzweig, and R. M. Steinman. 2000. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J. Cell Biol. 151: 673-684.
44. Kato, M., K. J. McDonald, S. Khan, I. L. Ross, S. Vuckovic, K. Chen, D. Munster, K. P. MacDonald, and D. N. Hart. 2006. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int. Immunol. 18: 857-869.
45. Tel, J., D. Benitez-Ribas, S. Hoosemans, A. Cambi, G. J. Adema, C. G. Figdor, P. J. Tacken, and I. J. de Vries. 2011. DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. Eur. J. Immunol. 41: 1014-1023.
46. Gräler, M. H., R. Grosse, A. Kusch, E. Kremmer, T. Gudermann, and M. Lipp. 2003. The sphingosine 1-phosphate receptor S1P4 regulates cell shape and motility via coupling to Gi and G12/13. J. Cell. Biochem. 89: 507-519.
47. Fabricius, D., M. Neubauer, B. Mandel, C. Schutz, A. Viardot, A. Vollmer, B. Jahrsdörfer, and K. M. Debatin. 2010. Prostaglandin E2 inhibits IFN-alpha secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement. J. Immunol. 184: 677-684.
48. Contractor, N., J. Louten, L. Kim, C. A. Biron, and B. L. Kelsall. 2007. Cutting edge: Peyer's patch plasmacytoid dendritic cells (pDCs) produce low levels of type I interferons: possible role for IL-10, TGFbeta, and prostaglandin E2 in conditioning a unique mucosal pDC phenotype. J. Immunol. 179: 2690-2694.
49. Bekeredjian-Ding, I., M. Schäfer, E. Hartmann, R. Pries, M. Parcina, P. Schneider, T. Giese, S. Endres, B. Wollenberg, and G. Hartmann. 2009. Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. Immunology 128: 439-450.
50. Jiang, L. I., J. Collins, R. Davis, I. D. Fraser, and P. C. Sternweis. 2008. Regulation of cAMP responses by the G12/13 pathway converges on adenylyl cyclase VII. J. Biol. Chem. 283: 23429-23439.
51. Haeryfar, S. M. 2005. The importance of being a pDC in antiviral immunity: The IFN mission versus Ag presentation? Trends Immunol. 26: 311-317.
52. Curtsinger, J. M., and M. F. Mescher. 2010. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 22: 333-340.
53. Lui, G., O. Manches, J. Angel, J. P. Molens, L. Chaperot, and J. Plumas. 2009. Plasmacytoid dendritic cells capture and cross-present viral antigens from influenza-virus exposed cells. PLoS One 4: e7111.
54. Sikora, A. G., N. Jaffarzad, Y. Hailemichael, A. Gelbard, S. W. Stonier, K. S. Schluns, L. Frasca, Y. Lou, C. Liu, H. A. Andersson, et al. 2009. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J. Immunol. 182: 7398-7407.
55. Starbeck-Miller, G. R., H. H. Xue, and J. T. Harty. 2014. IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining highaffinity IL-2 signaling in vivo. J. Exp. Med. 211: 105-120.
56. Golding, A., A. Rosen, M. Petri, E. Akhter, and F. Andrade. 2010. Interferonalpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology 131: 107-117.
57. Fuertes, M. B., A. K. Kacha, J. Kline, S. R. Woo, D. M. Kranz, K. M. Murphy, and T. F. Gajewski. 2011. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 208: 2005-2016.
58. Diamond, M. S., M. Kinder, H. Matsushita, M. Mashayekhi, G. P. Dunn, J. M. Archambault, H. Lee, C. D. Arthur, J. M. White, U. Kalinke, et al. 2011. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208: 1989-2003.
59. Sisirak, V., J. Faget, M. Gobert, N. Goutagny, N. Vey, I. Treilleux, S. Renaudineau, G. Poyet, S. I. Labidi-Galy, S. Goddard-Leon, et al. 2012. Impaired IFN-A production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 72: 5188-5197.
60. Labidi-Galy, S. I., I. Treilleux, S. Goddard-Leon, J. D. Combes, J. Y. Blay, I. Ray-Coquard, C. Caux, and N. Bendriss-Vermare. 2012. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. OncoImmunology 1: 380-382.
61. Kunkel, G. T., M. Maceyka, S. Milstien, and S. Spiegel. 2013. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat. Rev. Drug Discov. 12: 688-702.
62. Galicia-Rosas, G., N. Pikor, J. A. Schwartz, O. Rojas, A. Jian, L. Summers-Deluca, M. Ostrowski, B. Nuesslein-Hildesheim, and J. L. Gommerman. 2012. A sphingosine-1-phosphate receptor 1-directed agonist reduces central nervous system inflammation in a plasmacytoid dendritic cell-dependent manner. J. Immunol. 189: 3700-3706.
63. Gao, Y., B. Majchrzak-Kita, E. N. Fish, and J. L. Gommerman. 2009. Dynamic accumulation of plasmacytoid dendritic cells in lymph nodes is regulated by interferon-beta. Blood 114: 2623-2631.